Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
Overview
Overview
Journal
Antimicrob Agents Chemother
Publisher
American Society for Microbiology
Specialty
Pharmacology
Date
2020 Sep 2
PMID
32868326
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated with data from switch participants in the DRIVE-SHIFT trial and used to estimate individual PK parameter values and evaluate the efficacy exposure-response relationship. The results support the 100-mg dose for people living with HIV switching to a doravirine-based regimen (This study has been registered at ClinicalTrials.gov under ClinicalTrials registration no. NCT02397096.).
References
1.
Molina J, Squires K, Sax P, Cahn P, Lombaard J, DeJesus E
. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018; 5(5):e211-e220.
DOI: 10.1016/S2352-3018(18)30021-3.
View
2.
Greaves W, Wan H, Yee K, Kandala B, Vaddady P, Hwang C
. Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2019; 63(12).
PMC: 6879224.
DOI: 10.1128/AAC.01298-19.
View
3.
Orkin C, Squires K, Molina J, Sax P, Wong W, Sussmann O
. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2018; 68(4):535-544.
PMC: 6355823.
DOI: 10.1093/cid/ciy540.
View
4.
Nachega J, Mugavero M, Zeier M, Vitoria M, Gallant J
. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence. 2011; 5:357-67.
PMC: 3150164.
DOI: 10.2147/PPA.S22771.
View
5.
Yee K, Sanchez R, Auger P, Liu R, Fan L, Triantafyllou I
. Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects. Antimicrob Agents Chemother. 2016; 61(2).
PMC: 5278744.
DOI: 10.1128/AAC.01757-16.
View